Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
Peter Mohr, Emilie Scherrer, Chalid Assaf, Marc Bender, Carola Berking, Sheenu Chandwani, Thomas Eigentler, Imke Grimmelmann, Ralf Gutzmer, Sebastian Haferkamp, Jessica C. Hassel, Axel Hauschild, Rudolf Herbst, Ruixuan Jiang, Katharina C. Kähler, Clemens Krepler, Alexander Kreuter, Ulrike Leiter, Carmen Loquai, Friedegund Meier
*Corresponding author for this work
- Elbe-Kliniken
- Merck Sharp and Dohme
- Charite - Universitatsmedizin Berlin
- Helios Hospital Krefeld
- University of Erlangen–Nuremberg
- University of Tubingen
- Hannover Medical School
- Johannes Wesling Klinikum Minden
- University of Regensburg
- Ruprecht-Karls Universität Heidelberg
- University of Kiel
- HELIOS Klinikum Erfurt
- University Witten/Herdecke
- Johannes Gutenberg University Mainz
- Universitätsklinikum Carl Gustav Carus
- Saarland University
- QuintilesIMS
- University of Duisburg-Essen
- Helios Kliniken Schwerin
- Skin Cancer Center
- University of Mannheim
- German Cancer Research Center
- University of Münster
- Klinikum Augsburg
11
Link opens in a new tab
Citations
(Scopus)